Business Context and Reporting Period
Company: Globus Medical, Inc. (GMED)
Filing Type: Form 8-K (Current Report)
Date of Report: February 8, 2023
Event: Entry into a Material Definitive Agreement to acquire NuVasive, Inc.
On February 8, 2023, Globus Medical, Inc. entered into an Agreement and Plan of Merger with NuVasive, Inc. and a wholly-owned subsidiary, Zebra Merger Sub, Inc. The transaction provides for the merger of NuVasive into Globus Medical, with NuVasive surviving as a wholly-owned subsidiary.
Key Financial Metrics and Transaction Terms
This filing details the terms of a proposed merger rather than periodic financial performance metrics (revenue, profit, cash flow). Key financial terms of the transaction include:
- Merger Consideration: Each outstanding share of NuVasive common stock will be converted into the right to receive 0.75 shares of Globus Medical Class A common stock.
- Fractional Shares: Cash will be paid in lieu of fractional shares.
- Termination Fees:
- $120 Million: Payable by NuVasive to Globus Medical if NuVasive terminates for a superior proposal, changes its recommendation, or materially breaches solicitation restrictions. Also payable by Globus Medical to NuVasive if Globus Medical terminates for a superior proposal, changes its recommendation, or materially breaches solicitation restrictions.
- $75 Million: Reduced fee applicable if the change in recommendation or termination for a superior proposal occurs within the "Specified Period" (30 days following the agreement date, extendable by 5 days).
- $60 Million: Payable by NuVasive to Globus Medical if NuVasive stockholders fail to adopt the Merger Agreement and the board has not changed its recommendation.
- $120 Million: Payable by Globus Medical to NuVasive if Globus Medical stockholders fail to approve the issuance of shares or in the event of a breach of the Voting Agreement (reducible to $75 million under specific conditions).
Material Changes and Conditions
The consummation of the Merger is subject to several material conditions, including:
- Adoption of the Merger Agreement by NuVasive stockholders.
- Approval by Globus Medical stockholders of the issuance of shares.
- Effectiveness of the Form S-4 registration statement with the SEC.
- Expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act Approval).
- Absence of laws or orders prohibiting the Merger.
- No material adverse effect on either party since February 8, 2023.
Divestiture Covenant: Globus Medical is not required to divest any business, asset, property, or product line of NuVasive or Globus Medical that generated total net sales in excess of $40,000,000 in the twelve-month period ending December 31, 2022.
Outlook, Governance, and Risks
Board Composition: Upon closing, Globus Medical's board of directors will expand to eleven members, including three members proposed by NuVasive.
Voting Support: David Paul and Sonali Paul, holding approximately 70% of Globus Medical's total voting power (Class B Common Stock), have entered into a Voting Agreement to vote in accordance with the board's recommendation.
Timeline: The Merger must be completed by October 8, 2023, subject to two two-month extensions (maximum of 12 months from signing, or February 8, 2024) if HSR Act Approval has not been obtained or a legal restraint is in effect.
Risks and Contingencies: The filing highlights significant risks including failure to obtain shareholder or regulatory approvals, potential litigation, integration challenges, disruption to business operations, and the possibility that the transaction may not be completed on anticipated terms. Forward-looking statements regarding synergies and financial performance are subject to these uncertainties.
Investor Verification Checklist
- Verify the final exchange ratio of 0.75 Globus Medical shares for each NuVasive share.
- Monitor the status of the Form S-4 registration statement and the joint proxy statement/prospectus for detailed financial data and risk factors.
- Track the HSR Act waiting period expiration and any antitrust regulatory reviews.
- Confirm the outcome of the shareholder votes required at both NuVasive and Globus Medical.
- Review the Voting Agreement to understand the commitment of the Paul family (approx. 70% voting power) to support the transaction.
- Assess the potential impact of the $120 million termination fees on the financial stability of either party if the deal fails.